Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...
Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...
Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...
Brolucizumab stabilizes retinal exudation and fluid, improving visual outcomes in wet AMD management. Study showed BCVA and CRT improvements at 6 and 12 months, with minimal adverse events. Small ...
Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (OCUL) (NASDAQ: OCUL, “Ocular”, the “Company”), a ...
Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both dry and wet AMD. As highlighted by Huang and ...
ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to ...
A new study explains not only why some patients with wet age-related macular degeneration (or 'wet' AMD) fail to have vision improvement with treatment, but also how an experimental drug could be used ...
- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion ...
Opthea Ltd. is considering its options after lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD). The global Coast phase III trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback